Hauptmann Steffen, Denkert Carsten, Koch Ines, Petersen Simone, Schlüns Karsten, Reles Angela, Dietel Manfred, Petersen Iver
Institute of Pathology and Department of Gynecology and Obstetrics, Charité Hospital Berlin, Germany.
Hum Pathol. 2002 Jun;33(6):632-41. doi: 10.1053/hupa.2002.124913.
The genetic changes involved in the pathogenesis of ovarian carcinoma are not completely understood. To investigate this matter, we studied paraffin-embedded, microdissected tissue of 47 ovarian epithelial tumors (9 adenomas, 11 tumors of low malignant potential [LMP], 14 serous carcinomas, and 13 nonserous carcinomas) using comparative genomic hybridization (CGH). (The primary data used in this study are available at our CGH online tumor database at http://amba.charite.de/cgh.) Chromosomal imbalances were found in 1 serous adenoma and in 7 LMP tumors. In the latter the alterations appeared randomly and showed no overlap with alterations found in invasive carcinomas. Although the mean aberration number of low-grade serous carcinomas was comparable to LMP tumors, the imbalances of the former occurred with high incidence (>50%) and were found at different localizations. High-grade serous carcinomas had more than twice as much chromosomal imbalances as low-grade serous carcinomas and also had pronounced alterations. In serous carcinomas, gains were found on 3q, 6p, 7, 8q, and 20, and losses were found on 4q, 6q, 12q, 13q, and 16q. Comparing serous and nonserous carcinomas, the mean aberration number was comparable, but the number of high incidence changes was lower, and the most frequent imbalances were losses on 13q and gains on 20p. Overlapping alterations occurring in serous and nonserous carcinomas were gains on 3q and 6p, as well as losses on 4q. Chromosomal imbalances associated with poor prognosis of ovarian carcinomas were gains on 6p, 7q, and 13q and losses on 15q, 17p, 18q, and 21q. Our data indicate that serous LMP tumors and invasive carcinomas have different genetic aberrations, indicating that invasive carcinomas do not arise from preexisting serous LMP tumors. On the other hand, there are common genetic abnormalities in serous and nonserous carcinomas, suggesting that they have very early lesions in common but take different paths of further development.
卵巢癌发病机制中涉及的基因变化尚未完全明确。为研究这一问题,我们使用比较基因组杂交(CGH)技术,对47例卵巢上皮性肿瘤(9例腺瘤、11例低恶性潜能[LMP]肿瘤、14例浆液性癌和13例非浆液性癌)的石蜡包埋、显微切割组织进行了研究。(本研究使用的原始数据可在我们的CGH在线肿瘤数据库http://amba.charite.de/cgh上获取。)在1例浆液性腺瘤和7例LMP肿瘤中发现了染色体失衡。在后者中,这些改变随机出现,且与浸润性癌中发现的改变无重叠。虽然低级别浆液性癌的平均畸变数与LMP肿瘤相当,但前者的失衡发生率较高(>50%),且发生在不同部位。高级别浆液性癌的染色体失衡是低级别浆液性癌的两倍多,且也有明显改变。在浆液性癌中,在3q、6p、7、8q和20号染色体上发现了增益,在4q、6q、12q、13q和16q号染色体上发现了缺失。比较浆液性癌和非浆液性癌,平均畸变数相当,但高发生率改变的数量较少,最常见的失衡是13q号染色体缺失和20p号染色体增益。浆液性癌和非浆液性癌中出现的重叠改变是3q和6p号染色体增益以及4q号染色体缺失。与卵巢癌预后不良相关的染色体失衡是6p、7q和13q号染色体增益以及15q、17p、18q和21q号染色体缺失。我们的数据表明,浆液性LMP肿瘤和浸润性癌有不同的基因畸变,这表明浸润性癌并非起源于先前存在的浆液性LMP肿瘤。另一方面,浆液性癌和非浆液性癌存在共同的基因异常,这表明它们有非常早期的共同病变,但后续发展路径不同。